Kuo, Y., Yen, Y., Chen, Y., Kee, K., Hung, C., Lu, S., . . . Wang, J. (2021). Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol.
Citação norma ChicagoKuo, Yuan-Hung, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, and Jing-Houng Wang. "Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure." Front Oncol 2021.
Deismireacht MLAKuo, Yuan-Hung, et al. "Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure." Front Oncol 2021.
Rabhadh: D'fhéadfadh nach mbeadh na deismireachtaí seo 100% cruinn i gcónaí.